In this Issue
- Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla
- Lykos Appoints ‘Pharma Veterans’ to C-Suite
- Psyence Scoops Up Clairvoyant for Peanuts
- Mindstate’s Moxy Enters Phase I Trial
- Embattled Braxia Bought for $180k
- UK Gov. Unveils £400m Plan to Catalyse Clinical Trials
- GH Research Waiting on Tox Studies to Respond to FDA’s Clinical Hold
- Cydex Sues Bexson Over Psychedelic Salt Patents
- Other Stories
***
Lykos Scales Back Investigator-Initiated Trials Program, Refers Some Researchers to PharmAla
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue